Background
==========

Breast cancer (BC), the most frequent carcinoma diagnosed and cause of death among women, affects 1,676,660 women worldwide and causes 521,900 mortalities every year \[[@b1-medscimonit-23-1857]\]. The latest statistics have revealed that the morbidity and mortality rates associated with BC accounts for 29% and 14% of cancers, respectively, in the United States \[[@b2-medscimonit-23-1857]\]. Similarly, the incidence of BC in China is also increasing annually \[[@b3-medscimonit-23-1857]\]. Targeted drugs have been approved to treat HER2-positive BC, but resistance remains an inevitable outcome \[[@b4-medscimonit-23-1857]\]. BC is a molecularly heterogeneous disease \[[@b5-medscimonit-23-1857]\], and well-defined and effective molecular targets are still lacking. Therefore, the need to identify novel therapeutic targets for BC is urgent.

MicroRNAs (miRNAs) are highly conserved, small, noncoding, single-stranded RNAs with 19--24 nucleotides \[[@b6-medscimonit-23-1857]\]. miRNAs transcriptionally or post-transcriptionally regulate gene expression through binding to targeted mRNAs and influence the degradation and translation of mRNA \[[@b6-medscimonit-23-1857]\]. miRNAs regulate gene expression and the levels of proteins that act as oncogenes or cancer suppressors. Moreover, miRNAs are involved in various biological processes \[[@b7-medscimonit-23-1857]\], and accumulating evidence suggests that aberrant levels of miRNAs are linked to proliferation, angiogenesis, and metastasis in various human malignancies \[[@b8-medscimonit-23-1857]\]. With the development and application of molecular biology technology, a vital role for miRNAs in the diagnosis, prognosis, and therapy prediction of BC has been revealed \[[@b9-medscimonit-23-1857]--[@b11-medscimonit-23-1857]\]. The mature miRNA microRNA-101-3p (miR-101-3p, previously named miR-101) can be generated from miR-101-1 and miR-101-2 (the precursor miRNA, pre-miRNA). MiR-101-1 and miR-101-2 are located on different chromosomes and have different sequences, with diverse functions in the process of transcription \[[@b12-medscimonit-23-1857]\]. Several studies have revealed that miR-101-3p is down-regulated in BC \[[@b13-medscimonit-23-1857],[@b14-medscimonit-23-1857]\]. miR-101-3p inhibits proliferation, invasion, and metastasis via targeting Stathmin1 (STMN1) and CXCR7 \[[@b13-medscimonit-23-1857],[@b15-medscimonit-23-1857]\] and promotes apoptosis by targeting JAK2 in BC cells \[[@b14-medscimonit-23-1857]\]. Nevertheless, the precise mechanism of miR-101-3p in inhibiting neoplasia is still not entirely clear. Therefore, comprehensive analysis of the target gene networks and clinical value may help further clarify the function of miR-101-3p.

In recent years, the development of microarray technology has served as an effective measure to identify differentially expressed genes (DEGs) \[[@b16-medscimonit-23-1857]\]. DEGs can be found through different experimental treatments, and their biological functions can be speculated via known information. Microarray technology has provided new insight into the alteration of gene expression during tumorigenesis \[[@b17-medscimonit-23-1857]\]. Biomarkers associated with BC have been identified based on gene expression profiles. Several expression chips have confirmed the aberrant expression of miRNAs in BC and miRNAs influencing tumor behavior and progression \[[@b18-medscimonit-23-1857],[@b19-medscimonit-23-1857]\]. A massive amount of complex biological information data has been generated and has greatly deepened our understanding of BC. Comprehensive analysis of gene expression patterns may aid in the prevention, treatment, and determination of prognosis in BC.

In this study, datasets of miR-101 in patients with BC, including 781 tumors and 87 adjacent non-tumor breast tissues from The Cancer Genome Atlas (TCGA), were explored. Furthermore, we analyzed the gene expression profile to identify DEGs between the miR-101-3p transfected group and the negative control group of BC cells. Bioinformatics analysis was carried out to predict targets of miR-101-3p. The target genes acquired from Gene Expression Omnibus (GEO) and prediction software were combined, and their potential roles were further explored with pathway, Gene Ontology (GO), and network analyses. The present study explored the comprehensive roles and prospective molecular mechanisms of miR-101-3p and might facilitate the discovery of potential novel biomarkers for future investigation of the mechanisms involved in BC.

Material and Methods
====================

Patients in TCGA database
-------------------------

MiR-101 (miR-101-1 and miR-101-2) sequence data of BC were obtained from the TCGA dataset on 15 May 2016; the dataset included 781 patients with BC and 87 adjacent noncancerous breast tissues. In BC, the expression levels of log~2~-transformed miR-101-1 and miR-101-2 were analyzed, as was their correlation with survival data and clinical parameters.

Retrieval of BC gene expression microarray data
-----------------------------------------------

Microarray data for miR-101-3p transfected in BC cells were searched in Gene Expression Omnibus (GEO, *<http://www.ncbi.nlm.nih.gov/geo/>*). The array data for GSE31397 were retrieved as raw data files based on the GPL570 platform (Affymetrix Human Genome U133 Plus 2.0 Array; Affymetrix, Inc., Santa Clara, CA). The alterations in miR-101-3p transfected MCF-7 cells compared with scramble control transfected cells were included in the expression profiling.

Data preprocessing and DEG analysis
-----------------------------------

The Affymetrix package \[[@b20-medscimonit-23-1857]\] in R language preprocessed the original data, and probe-level data were mapped to gene names. The DEGs between the miR-101-3p transfected cells and the control group were identified with the limma package of R language \[[@b21-medscimonit-23-1857]\]. Down-regulated DEGs were determined with the criteria of fold change \>2.5 and *P* value \<0.05.

Prediction of miRNA-3p target genes
-----------------------------------

Potential target genes of miR-101-3p were predicted by 13 online databases: DIANAmT, mirTarBase, RNA22, miRanda, PICTAR, miRDB, miRWalk, PolymiRTS, PITA, RNAhybrid, Targetscan, Targetminer, and TarBase. Targets were acquired from the DGEs in GEO and the predicted genes that were identified in more than 5 out of 13 programs. Moreover, the experimental validation of the targets using a luciferase reporter assay, WB, and RT-PCR was collected from TarBase, mirTarBase, and published studies.

GO, KEGG and network analysis
-----------------------------

To discern the biological attributes of the putative target genes, GO and KEGG enrichment analyses were completed using DAVID (*<https://david.ncifcrf.gov>*, version 6.7) \[[@b22-medscimonit-23-1857]\]. The functional network graph of the selected genes was further visualized with Cytoscape 3.3.0 \[[@b23-medscimonit-23-1857]\].

Statistical analysis
--------------------

SPSS 20.0 was used for data analysis; data are presented as the mean ± standard deviation (SD). Statistical significance was assessed with a 2-sample *t* test between the cancer samples and adjacent noncancerous tissues and the correlation between miR-101-3p and clinical features. Survival data were determined with the Kaplan-Meier method. *P*\<0.05 represented statistical significance.

Results
=======

Clinical significance of miR-101 (miR-101-1 and miR-101-2) in BC based on TCGA data
-----------------------------------------------------------------------------------

The miR-101-2 expression level was lower in BC than in the normal cells, but this difference was not statistically significant ([Figure 1A, 1D](#f1-medscimonit-23-1857){ref-type="fig"}). A receiver operating characteristic (ROC) curve was constructed to identify diagnostic value in the cases of BC compared with non-cancer breast tissues. The area under the curve (AUC) of miR-101-1 was 0.56 (95% CI: 0.50--0.62), with a sensitivity and specificity of 51.0% and 62.1%, respectively ([Figure 1B](#f1-medscimonit-23-1857){ref-type="fig"}). The AUC of miR-101-2 was 0.63 (95% CI: 0.58--0.68), with a sensitivity and specificity of 83.9% and 44.8%, respectively ([Figure 1E](#f1-medscimonit-23-1857){ref-type="fig"}). In the analysis of miR-101 and clinical parameters, miR-101-1 was prominently associated with the expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in BC ([Table 1](#t1-medscimonit-23-1857){ref-type="table"}). MiR-101-2 was significantly associated with tumor (T), lymph node (N), and metastasis (M) stages of BC ([Table 2](#t2-medscimonit-23-1857){ref-type="table"}). Moreover, decreased miR-101-1 expression revealed a poor prognosis in BC (HR=1.79; 95% CI: 1.06--3.01; *P*=0.028) ([Figure 1C](#f1-medscimonit-23-1857){ref-type="fig"}). However, no significant prognostic value was identified for miR-101-2 in BC (HR=1.423, 95% CI: 0.84--2.41; *P*=0.183) ([Figure 1F](#f1-medscimonit-23-1857){ref-type="fig"}).

Potential targets of miR-101-3p in BC
-------------------------------------

As shown in [Figure 2](#f2-medscimonit-23-1857){ref-type="fig"}, GSE31397 array data were acquired, and 921 genes were selected as differentially expressed in miR-101-3p transfected MCF-7 cells compared with scramble control cells. In addition, the online prediction process was conducted with 13 databases to obtain potential targets of miR-101-3p, and 7924 genes were identified after duplicated genes were excluded. The genes predicted by 5 out of 13 programs were selected, and then 377 target genes were searched from the array data and predicted targets. Furthermore, 69 available genes that were identified as targets of miR-101-3p through TarBase, miTarBase and published literature were included ([Table 3](#t3-medscimonit-23-1857){ref-type="table"}). Eventually, a total of 427 genes were identified for the gene-annotation enrichment analysis and KEGG pathway analysis.

Gene-annotation enrichment analysis and KEGG pathway analysis
-------------------------------------------------------------

Selecting *Homo sapiens* as the background of listed target genes in DAVID, we obtained the GO term annotations and KEGG pathway analysis through the functional annotation summaries. An EASE Score or modified Fisher's exact test was utilized for calculating the *p* value. The results of the GO analysis are summarized in [Table 4](#t4-medscimonit-23-1857){ref-type="table"} and [Figure 3](#f3-medscimonit-23-1857){ref-type="fig"}, and the top 10 enriched items are listed according to *p* values. The biological processes (BP) of the potential targets of miR-101-3p markedly focused on the gene expression, transcription, metabolism, biosynthesis, and proliferation processes (p\<0.001). As for the cellular component (CC), the target genes were significantly located in insoluble, cell, and membrane fractions (p\<0.001). Moreover, molecular function (MF) category was enriched in transcription factors and proteins involved in nucleotide binding (p\<0.001). In terms of the KEGG pathway analysis, the results were notably enriched in pathways involved in cancer, renal cell carcinoma, and colorectal cancer. Moreover, results were highly enriched in the VEGF, mTOR, focal adhesion, Wnt, chemokine, ErbB, and p53 signaling pathways (p\<0.05, [Table 5](#t5-medscimonit-23-1857){ref-type="table"} and [Figure 4](#f4-medscimonit-23-1857){ref-type="fig"}). The enrichment graphs for the potential target genes were generated with Cytoscape software. As shown in [Figure 5](#f5-medscimonit-23-1857){ref-type="fig"}, the clearly associated functional modules were metabolism, development, cellular, and biological processes in BP. Analysis of CC revealed the most correlated functions were membrane and intracellular fractions ([Figure 6](#f6-medscimonit-23-1857){ref-type="fig"}). In the MF network, protein and transcription factor binding were the top results ([Figure 7](#f7-medscimonit-23-1857){ref-type="fig"}).

Discussion
==========

miRNAs play vital roles in BC, and an increasing amount of research has made important contributions to this field. MiRNAs, including miR-21/9/10b/27a/155, were overexpressed in BC, while miR-31/34a/125/205 were down-regulated during BC progression \[[@b24-medscimonit-23-1857], [@b25-medscimonit-23-1857]\]. Zhao et al. \[[@b26-medscimonit-23-1857]\] demonstrated that miR-221 may be a predictive biomarker for BC. In the research of Eissa et al. \[[@b27-medscimonit-23-1857]\], patients with BC positive for miR-10b had shorter relapse-free survival rates, and miR-10b was an independent prognostic factor of BC. MiR-451 influenced the drug resistances and miR-129-5p regulated radiosensitivity via accelerating the apoptosis of breast cancer cells \[[@b28-medscimonit-23-1857],[@b29-medscimonit-23-1857]\]. Peptide nucleic acid (PNA) has been researched as a novel drug in miRNA therapeutics, but has still not been successfully used to treat BC \[[@b30-medscimonit-23-1857],[@b31-medscimonit-23-1857]\]. Recently, decreased miR-101-3p levels were observed in tumors, including colon, gastric, lung, ovary, and prostate cancers \[[@b32-medscimonit-23-1857]\]. miR-101-3p has important roles in the tumorigenesis of BC; however, the mechanisms and target genes of miR-101-3p are still unknown.

TCGA data demonstrated that miR-101-2 expression was lower in BC tissues than in normal tissues, while no statistical difference was shown for miR-101-1 expression. MiR-101-1 was also closely linked to ER, PR, and HER2, while miR-101-2 was associated with the T, N, and M stages of BC. This result revealed that miR-101-2 may have diagnostic value in BC to some extent. Down-regulated miR-101-1 was associated with poor prognosis in patients with BC, while no statistical significance was found for miR-101-2. miR-101 has 2 genomic *loci*, with miR-101-1 being located on chromosome 1p31.3 and miR-101-2 located on chromosome 9p24.1 \[[@b33-medscimonit-23-1857]\]. This result revealed that the miR-101 transcripts on different chromosomes play diverse roles in the diagnosis, prognosis, and clinical outcome of BC. MiR-101-1 is processed into miR-101-3p and miR-101-5p, while miR-101-2 only produces mature miR-101-3p. In addition, the different sequences of miR-101-1 and miR-101-2 will promote or restrict different targets through participation in the translation process and reveal different biological functions \[[@b12-medscimonit-23-1857]\]. However, it was difficult to extrapolate the mature miRNA levels (which are the final cellular effectors) based on these data. One precursor may be processed to 1 or 2 miRNAs; thus, the mature and precursor miRNA levels might not correlate, and this therefore will influence the clinical interpretation.

Putative miR-101-3p targets were derived from the expression profiling of miR-101-3p transfected in MCF-7 cells compared with scramble control cells, online prediction databases, validated targets, and published studies. Among the 427 putative target genes, the most predominant functions were transcription, metabolism, biosynthesis, proliferation, and transcription factor binding. This result indicated that candidate genes have a definitive impact on the pathogenesis of BC. In previous studies, 8 targets of miR-101-3p were validated in BC: AMP-activated protein kinase (AMPK), CX chemokine receptor 7 (CXCR7), eyes absent homolog 1 (EYA1), janus kinase 2 (JAK2), membrane-associated guanylate kinase 2 (MAGI2), myeloid cell leukemia 1 (Mcl-1), Stathmin1 (STMN1), and von Hippel-Lindau tumor suppressor (VHL). AMPK was found to regulate tumor metabolism and be targeted by mir-101-3p and was identified as a promising therapeutic target in triple-negative breast cancer (TNBC) \[[@b34-medscimonit-23-1857]\]. miR-101-3p inhibited the development and lymph node metastasis of BC via targeting CXCR7 \[[@b15-medscimonit-23-1857]\]. The latest research by Guan et al. \[[@b35-medscimonit-23-1857]\] showed that miR-101-3p was down-regulated and inhibited cell proliferation and promoted apoptosis by targeting EYA1 in BC. JAK2 has been verified to participate in suppressing proliferation and promoting apoptosis in BC cells through miR-101-3p \[[@b14-medscimonit-23-1857]\]. Sachdeva et al. \[[@b36-medscimonit-23-1857]\] demonstrated that miR-101-3p reduced phosphatase and tensin homolog (PTEN) activity by suppressing MAGI-2, leading to Akt activation. MiR-101-3p, which directly inhibited MCL-1, was reported to restrain cell progression and increase sensitivity to paclitaxel in TNBC \[[@b37-medscimonit-23-1857]\]. In a study by Wang et al. \[[@b13-medscimonit-23-1857]\], the down-regulation of miR-101-3p was confirmed to regulate STMN1, and was associated with cellular proliferation and invasiveness in different subtypes of BC tissues. Moreover, miR-101-3p enhanced apoptosis and cell cycle arrest by down-regulating VHL expression in normoxic conditions \[[@b38-medscimonit-23-1857]\].

Several studies have reported the signaling pathways associated with miR-101-3p in BC. miR-101-3p inhibited CXCR7-STAT3 signaling and exerted tumor-suppressive effects in BC cells \[[@b15-medscimonit-23-1857]\]. Down-regulated miR-101-3p suppressed cell proliferation through the Notch signaling pathway in BC \[[@b34-medscimonit-23-1857]\]. Furthermore, estrogen deprivation enhanced the miR-101-3p-mediated activation of the Akt signaling pathway \[[@b36-medscimonit-23-1857]\]. In this paper, a total of 26 bio-pathways were identified, and analysis of miR-101-3p targets revealed statistical significance for 21 pathways. In addition, the visualized network graph of miR-101-3p-mediated targets in Cytoscape showed biological functions similar to the DAVID analysis mentioned above. The highly connected targets are involved in important biological processes and molecular functions.

Among the pathways of the miR-101-3p targeted genes, the VEGF, mTOR, focal adhesion, Wnt, chemokine, ErbB, and p53 signaling pathways were highly enriched. The VEGF signaling pathway enhanced angiogenesis for the aggressive proliferation and malignant progression of BC \[[@b39-medscimonit-23-1857]\]. The PI3K/Akt/mTOR signaling pathway plays a vital regulatory function in proliferation, apoptosis, metabolism, and migration, and the invasion of BC can be alleviated by miR-199a-5p via targeting the FAK/Src/Akt/mTOR signaling pathway \[[@b40-medscimonit-23-1857]\]. Focal adhesion kinase (FAK) regulates cell motility, extracellular matrix integrin signaling, cell proliferation, and survival. MiR-7 inhibited cell transformation and the metastasis of BC via regulating FAK, which is correlated with a poor prognosis \[[@b41-medscimonit-23-1857]\]. The chemokine signaling pathway mediates chemokines and promotes the chemotaxis, growth, and survival of BC cells \[[@b42-medscimonit-23-1857]\]. miR-195 suppressed the Wnt signaling pathway, which promotes cell proliferation and the metastasis of TNBC \[[@b43-medscimonit-23-1857]\]. Han et al. reported that the ErbB signaling pathway can be regulated by STAT1 in the tumorigenesis of BC \[[@b44-medscimonit-23-1857]\]. Furthermore, scaffold/matrix-associated region-binding protein 1 (SMAR1) may increase radiosensitivity in the MCF-7 BC cell line by regulating the p53 signaling pathway \[[@b45-medscimonit-23-1857]\]. Enrichment analysis of the potential pathways revealed that the Wnt signaling pathway probably regulates the cell cycle, metabolism, and phosphorylation by targeting CCND3 and ROCK. MAPK1, MTOR, and VEGFA may contribute to metabolism and biosynthesis, which are associated with the mTOR signaling pathway. The VEGF signaling pathway is involved in proliferation and apoptosis via targeting MAPK1, RAC1, NRAS, and VEGFA. The chemokine, focal adhesion, mTOR, VEGF, and ErbB signaling pathways might influence metabolism, phosphorylation, kinase activity, and intracellular signaling cascades by regulating PIK3CB. However, the interaction of target genes and their signaling pathways, as well as their molecular mechanisms, should be further explored.

Conclusions
===========

This study is a comprehensive target analysis of the miR-101 using gene expression profiling, public databases, and prediction software. MiR-101 plays vital roles in BC, while the products derived from different locations on different chromosomes did not show the same functions. The genes targeted by miR-101-3p influence the progression of BC and might influence the biological functions performed by the VEGF, mTOR, focal adhesion, Wnt, and chemokine signaling pathways by targeting crucial genes. The mechanisms of novel molecular markers should be further verified with new techniques, and will contribute to the diagnosis and treatment of BC.
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![The biological process (BP) network of miR-101-3p targeted genes was constructed using Cytoscape. The color and size of the nodes indicate the significance of the interactions.](medscimonit-23-1857-g005){#f5-medscimonit-23-1857}

![The cellular component (CC) network of miR-101-3p targeted genes was constructed using Cytoscape. The color and size of the nodes indicate the significance of the interactions.](medscimonit-23-1857-g006){#f6-medscimonit-23-1857}

![The molecular function (MF) network of miR-101-3p targeted genes was constructed using Cytoscape. The color and size of the nodes indicate the significance of the interactions.](medscimonit-23-1857-g007){#f7-medscimonit-23-1857}

###### 

Correlation of miR-101-1 expression with clinical parameters in BC of TCGA data.

  Clinicopathological features   Cases      MiR-101-1 expression   *P* value         
  ------------------------------ ---------- ---------------------- ----------- ----- ---------
  Age                            ≥50        563                    291         272   0.254
  \<50                           218        99                     119               
  Gender                         Female     772                    382         390   0.241
  Male                           9          8                      1                 
  T                              T1--T2     657                    338         319   0.086
  T3--T4                         123        52                     71                
  N                              N0         373                    183         190   0.546
  N1--N3                         398        205                    193               
  M                              M0         610                    325         285   0.298
  M1                             9          2                      7                 
  Stage                          I--II      587                    290         297   0.782
  III--IV                        186        94                     92                
  ER                             Positive   565                    259         306   \<0.001
  Negative                       170        111                    59                
  PR                             Positive   502                    221         281   \<0.001
  Negative                       231        148                    83                
  HER2                           Positive   99                     57          42    0.037
  Negative                       397        202                    195               

T -- tumor stage; N -- lymph node stage; M -- metastasis stage; ER -- estrogen receptor; PR -- progesterone receptor; HER2 -- human epidermal growth factor receptor 2. The median was chosen as the cut-off value because of the skewed distribution of the expression data.

###### 

Correlation between miR-101-2 expression and clinical parameters in BC from the TCGA data.

  Clinicopathological features   Cases      MiR-101-2 expression   *P* value         
  ------------------------------ ---------- ---------------------- ----------- ----- -------
  Age                            ≥50        563                    287         276   0.150
  \<50                           218        104                    114               
  Gender                         Female     772                    385         387   0.485
  Male                           9          6                      3                 
  T                              T1--T2     657                    343         314   0.008
  T3--T4                         123        48                     75                
  N                              N0         373                    200         173   0.029
  N1--N3                         398        187                    211               
  M                              M0         610                    343         267   0.017
  M1                             9          2                      7                 
  Stage                          I--II      587                    298         289   0.129
  III--IV                        186        88                     98                
  ER                             Positive   565                    275         290   0.058
  Negative                       170        88                     82                
  PR                             Positive   502                    245         257   0.250
  Negative                       231        118                    113               
  HER2                           Positive   99                     54          55    0.481
  Negative                       397        207                    190               

T -- tumor stage; N -- lymph node stage; M -- metastasis stage; ER -- estrogen receptor; PR -- progesterone receptor; HER2 -- human epidermal growth factor receptor 2. The median was chosen as the cut-off value because of the skewed distribution of the expression data.

###### 

Validated targets of miR-101-3p in TarBase, miTarBase and published literatures.

                    Genes                                                  
  ----------------- ---------- ---------- ---------- ---------- ---------- ---------
  All validated     *ABCA1*    *CFTR*     *EZB2*     *MCL1*     *PTGS2*    *SUZ12*
  *AMPK*            *c-Met*    *EZH2*     *Mcl-1*    *RAB5A*    *TET2*     
  *AP1*             *COX2*     *FBN2*     *MEIS1*    *Rac1*     *TGFBR1*   
  *APP*             *CPEB1*    *FMR1*     *MET*      *RAP1B*    *VEGF*     
  *ARID1A*          *CXCL12*   *FOS*      *MITF*     *RLIP76*   *VEGFA*    
  *ATG4D*           *CXCR7*    *HMGA2*    *MTOR*     *ROCK2*    *VEGF-C*   
  *ATM*             *DNMT3A*   *JAK2*     *MYCN*     *RUNX1*    *VHL*      
  *ATP5B*           *DUSP1*    *KLF6*     *NLK*      *SOCS2*    *ZEB1*     
  *ATXN1*           *EED*      *Lin28B*   *PIK3CB*   *SOX9*     *ZEB2*     
  *CASP3*           *EP4*      *MAGI2*    *Pim1*     *SphK1*               
  *CDH5*            *EYA1*     *MAPK1*    *PRDM16*   *STMN1*               
  *CDK8*            *EZB1*     *MARCH7*   *PTGER4*   *Stmnl*               
  Validated in BC   *CXCR7*    *JAK2*     *MAPK*     *STMN1*               
  *EYA1*            *MAGI2*    *Mcl-1*    *VHL*                            

###### 

GO functional annotation for the significant targets of miR-101-3p as determined by DAVID.

  GO ID                    GO term                                                       Count (%)   *P* value     Gene symbol
  ------------------------ ------------------------------------------------------------- ----------- ------------- -----------------------------------------------------------------
  **Biological process**                                                                                           
  GO: 0010629              Negative regulation of gene expression                        31 (0.4)    6.89×10^−6^   *GCLC, THRB, CBX4, ZEB2, ZEB1, SOX9, PRDM16, LIN28B etc.*
  GO: 0006357              Regulation of transcription from RNA polymerase ii promoter   39 (0.5)    8.52×10^−6^   *THRB, MITF, CBX4, ZEB1, PRDM16, SOX9, MED20, FOS etc.*
  GO: 0010604              Positive regulation of macromolecule metabolic process        43 (0.6)    1.36×10^−5^   *GCLC, THRB, MITF, ZEB1, PRDM16, SOX9, FOS, APP, MEIS2 etc.*
  GO: 0009891              Positive regulation of biosynthetic process                   37 (0.5)    1.83×10^−5^   *THRB, MITF, ZEB1, ABCA1, PRDM16, SOX9, FOS, APP etc.*
  GO: 0006325              Chromatin organization                                        25 (0.4)    2.10×10^−5^   *EZH2, NAP1L1, CBX4, CDYL, H2AFV, SMARCD1 etc.*
  GO: 0051173              Positive regulation of nitrogen compound metabolic process    35 (0.5)    2.15×10^−5^   *THRB, MITF, ZEB1, ABCA1, PRDM16, SOX9, FOS, APP etc.*
  GO: 0031328              Positive regulation of cellular biosynthetic process          36 (0.5)    3.20×10^−5^   *THRB, MITF, ZEB1, ABCA1, PRDM16, SOX9, FOS, APP etc.*
  GO: 0008284              Positive regulation of cell proliferation                     26 (0.4)    3.24×10^−5^   *NRP1, PTGS2, MARCKSL1, NAP1L1, CD47, AGGF1, TGFA etc.*
  GO: 0016568              Chromatin modification                                        20 (0.3)    4.74×10^−5^   *DNMT3A, AEBP2, UBE2A, EZH2, CBX4, ARID1A, RBBP7, UBE2B etc.*
  GO: 0042127              Regulation of cell proliferation                              39 (0.6)    4.94×10^−5^   *NRP1, PTGS2, MARCKSL1, MITF, NAP1L1, ZEB1, SOX9, CDH5 etc.*
  **Cellular component**                                                                                           
  GO: 0005626              Insoluble fraction                                            43 (0.6)    3.83×10^−7^   *GALNT3, GNAI3, PTGS2, PLXNA1, HMGCR, SGPP1, ADCY6 etc.*
  GO: 0000267              Cell fraction                                                 49 (0.7)    1.78×10^−6^   *RAB3GAP2, PLXNA1, PTGS2, HMGCR, SGPP1, ADCY6, SLC26A2 etc.*
  GO: 0005624              Membrane fraction                                             40 (0.6)    2.65×10^−6^   *GALNT3, GNAI3, PTGS2, PLXNA1, HMGCR, SGPP1, ADCY6 etc.*
  GO: 0005694              Chromosome                                                    28 (0.4)    3.14×10^−6^   *HMGB3, CBX4, CDYL, SIN3A, H2AFV, PAFAH1B1, CHD6, TOP2B etc.*
  GO: 0044427              Chromosomal part                                              25 (0.4)    4.29×10^−6^   *CBX4, CDYL, SIN3A, H2AFV, PAFAH1B1, TOP2B, CHD6 etc.*
  GO: 0000785              Chromatin                                                     17 (0.2)    8.35×10^−6^   *DNMT3A, UBE2A, PDS5B, CBX4, HMGA2, UBE2B, JUNB, MYCN etc.*
  GO: 0009898              Internal side of plasma membrane                              21 (0.3)    2.14×10^−5^   *RAP2C, RAB39B, AP1G1, MAOB, PIP5K1C, SNAPIN, CTNNA1 etc.*
  GO: 0019898              Extrinsic to membrane                                         27 (0.4)    3.26×10^−5^   *PTGS2, CHMP5, ARHGAP17, MTMR2, DMXL2, PVRL1, RAC1 etc.*
  GO: 0031974              Membrane-enclosed lumen                                       65 (0.9)    1.10×10^−4^   *MRPL42, PTGS2, ZMAT3, ATP5B, EZH2, DNAJC10, ZEB1 etc.*
  GO: 0043233              Organelle lumen                                               64 (0.9)    1.13×10^−4^   *MRPL42, PTGS2, ZMAT3, ATP5B, EZH2, DNAJC10, ZEB1, WTAP etc.*
  **Molecular function**                                                                                           
  GO: 0008134              Transcription factor binding                                  33 (0.5)    2.25×10^−6^   *THRB, CBX4, ZEB1, PRDM16, CBFA2T2, RAB1A, TMF1 etc.*
  GO: 0000166              Nucleotide binding                                            85 (1.2)    7.96×10^−5^   *CPEB2, HMGCR, ATP5B, UBE2G1, ADCY6, PIP5K1C, HELZ etc.*
  GO: 0046332              SMAD binding                                                  8 (0.1)     1.41×10^−4^   *FOS, TGFBR1, ZEB2, SMAD2, SMAD1, PRDM16, PURB, PURA*
  GO: 0003690              Double-stranded DNA binding                                   11 (0.2)    1.66×10^−4^   *KLF6, FOS, ANKRD17, THRB, SMAD2, ZEB1, PURB etc.*
  GO: 0030528              Transcription regulator activity                              60 (0.9)    4.17×10^−4^   *THRB, ELF5, EZH2, MITF, CBX4, ZEB2, ZEB1, LASS6, CBFA2T2 etc.*
  GO: 0003682              Chromatin binding                                             13 (0.2)    4.22×10^−4^   *ATRX, SUZ12, DNMT3A, CDYL, EZH2, MITF, SMARCA5, CBX4 etc.*
  GO: 0003702              RNA polymerase II transcription factor activity               17 (0.2)    4.79×10^−4^   *CEBPA, RXRB, MITF, TEAD3, SMAD1, SOX9, MED20, MEIS1 etc.*
  GO: 0032553              Ribonucleotide binding                                        68 (1.0)    1.02×10^−3^   *UBE2G1, ATP5B, ADCY6, PIP5K1C, HELZ, RAB1A, ANKRD17 etc.*
  GO: 0032555              Purine ribonucleotide binding                                 68 (1.0)    1.02×10^−3^   *UBE2G1, ATP5B, ADCY6, PIP5K1C, HELZ, RAB1A, ANKRD17 etc.*
  GO: 0043566              Structure-specific DNA binding                                12 (0.2)    1.13×10^−3^   *KLF6, FOS, ANKRD17, THRB, SUB1, SMAD2, ZEB1, PURB etc.*

###### 

KEGG pathway enrichment analysis of miR-101-3p target genes by DAVID.

  KEGG ID    KEGG term                              Count (%)   *P* value     Gene symbol
  ---------- -------------------------------------- ----------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa05200   Pathways in cancer                     25 (0.4)    1.41×10^−5^   *PTGS2, MITF, FOS, CASP3, RAC1, TGFA, RUNX1, CEBPA, RXRB, PIK3CB, VHL, TGFBR1, MET, ITGA2, SMAD2, CDK6, CTNNA1, STK4, FZD4, FZD6, NRAS, MAPK1, CDKN1A, VEGFA, MTOR*
  hsa05211   Renal cell carcinoma                   10 (0.1)    1.44×10^−4^   *MAPK1, NRAS, VHL, PIK3CB, MET, VEGFA, GAB1, RAC1, TGFA, RAP1B*
  hsa05210   Colorectal cancer                      10 (0.1)    5.79×10^−4^   *MAPK1, FOS, CASP3, PIK3CB, TGFBR1, MET, RAC1, SMAD2, FZD4, FZD6*
  hsa04520   Adherens junction                      9 (0.1)     1.44×10^−3^   *PTPRJ, MAPK1, PVRL1, NLK, TGFBR1, MET, RAC1, SMAD2, CTNNA1*
  hsa05223   Non-small cell lung cancer             7 (0.1)     4.05×10^−3^   *MAPK1, NRAS, PIK3CB, RXRB, TGFA, CDK6, STK4*
  hsa05212   Pancreatic cancer                      8 (0.1)     4.15×10^−3^   *MAPK1, PIK3CB, TGFBR1, VEGFA, RAC1, TGFA, CDK6, SMAD2*
  hsa05221   Acute myeloid leukemia                 7 (0.1)     5.79×10^−3^   *CEBPA, MAPK1, NRAS, PIK3CB, PIM1, MTOR, RUNX1*
  hsa05221   Glioma                                 7 (0.1)     8.65×10^−3^   *MAPK1, NRAS, CDKN1A, PIK3CB, TGFA, CDK6, MTOR*
  hsa04310   Wnt signaling pathway                  11 (0.16)   1.06×10^−2^   *PSEN1, CCND3, VANGL1, ROCK2, NLK, RAC1, SMAD2, PLCB1, FBXW11, FZD4, FZD6*
  hsa05218   Melanoma                               7 (0.1)     1.52×10^−2^   *MAPK1, NRAS, CDKN1A, PIK3CB, MET, MITF, CDK6*
  hsa04150   mTOR signaling pathway                 6 (0.1)     1.56×10^−2^   *MAPK1, PIK3CB, VEGFA, PRKAA1, MTOR, DDIT4*
  hsa04120   Ubiquitin mediated proteolysis         10 (0.1)    1.57×10^−2^   *UBE2D3, FBXW7, UBE2A, VHL, UBE2G1, UBE2F, CUL4B, UBE2D1, FBXW11, UBE2B*
  hsa04062   Chemokine signaling pathway            12 (0.2)    1.71×10^−2^   *MAPK1, NRAS, GNAI3, ROCK2, GNB1, PIK3CB, ADCY6, RAC1, RAP1B, JAK2, PLCB1, CXCL12*
  hsa04670   Leukocyte transendothelial migration   9 (0.1)     1.88×10^−2^   *F11R, GNAI3, ROCK2, PIK3CB, RAC1, RAP1B, CTNNA1, CXCL12, CDH5*
  hsa04370   VEGF signaling pathway                 7 (0.1)     1.94×10^−2^   *MAPK1, NRAS, PTGS2, PIK3CB, VEGFA, SPHK1, RAC1*
  hsa05220   Chronic myeloid leukemia               7 (0.1)     1.94×10^−2^   *MAPK1, NRAS, CDKN1A, PIK3CB, TGFBR1, CDK6, RUNX1*
  hsa04916   Melanogenesis                          8 (0.1)     2.22×10^−2^   *MAPK1, NRAS, GNAI3, MITF, ADCY6, PLCB1, FZD4, FZD6*
  hsa04510   Focal adhesion                         12 (0.2)    2.76×10^−2^   *MAPK1, CCND3, ROCK2, PIK3CB, MET, VEGFA, RAC1, ITGA2, PIP5K1C, RAP1B, CAPN2, PARVA*
  hsa04360   Axon guidance                          9 (0.1)     3.02×10^−2^   *MAPK1, NRAS, NRP1, GNAI3, PLXNA1, ROCK2, MET, RAC1, CXCL12*
  hsa04012   ErbB signaling pathway                 7 (0.1)     3.70×10^−2^   *MAPK1, NRAS, CDKN1A, PIK3CB, GAB1, TGFA, MTOR*
  hsa04115   p53 signaling pathway                  6 (0.1)     4.36×10^−2^   *CDKN1A, CASP3, CCND3, ZMAT3, CDK6, ATM*
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